Singapore markets closed

Agios Pharmaceuticals, Inc. (AGIO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
46.61-1.07 (-2.24%)
At close: 04:00PM EDT
46.98 +0.37 (+0.79%)
After hours: 04:54PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 2.71B
Enterprise value 2.18B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)90.70
Price/book (mrq)3.64
Enterprise value/revenue 74.05
Enterprise value/EBITDA -2.33

Trading information

Stock price history

Beta (5Y monthly) 0.78
52-week change 373.26%
S&P500 52-week change 322.23%
52-week high 349.06
52-week low 319.80
50-day moving average 341.16
200-day moving average 329.48

Share statistics

Avg vol (3-month) 3811.27k
Avg vol (10-day) 3672.18k
Shares outstanding 556.77M
Implied shares outstanding 656.77M
Float 847.37M
% held by insiders 11.48%
% held by institutions 1110.78%
Shares short (28 Jun 2024) 43.13M
Short ratio (28 Jun 2024) 42.9
Short % of float (28 Jun 2024) 45.59%
Short % of shares outstanding (28 Jun 2024) 45.51%
Shares short (prior month 31 May 2024) 44.47M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024


Profit margin 0.00%
Operating margin (ttm)-1,124.34%

Management effectiveness

Return on assets (ttm)-24.55%
Return on equity (ttm)-39.61%

Income statement

Revenue (ttm)29.4M
Revenue per share (ttm)0.53
Quarterly revenue growth (yoy)46.00%
Gross profit (ttm)N/A
EBITDA -386.76M
Net income avi to common (ttm)-352.62M
Diluted EPS (ttm)-6.31
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)597.99M
Total cash per share (mrq)10.53
Total debt (mrq)68.35M
Total debt/equity (mrq)9.19%
Current ratio (mrq)12.84
Book value per share (mrq)13.11

Cash flow statement

Operating cash flow (ttm)-300.75M
Levered free cash flow (ttm)-221.81M